NasdaqCM:CELC

Stock Analysis Report

Executive Summary

Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Celcuity's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.4%

CELC

1.6%

US Biotechs

0.4%

US Market


1 Year Return

-43.2%

CELC

-7.7%

US Biotechs

6.9%

US Market

Return vs Industry: CELC underperformed the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: CELC underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

CELCIndustryMarket
7 Day0.4%1.6%0.4%
30 Day-8.9%-2.4%-1.2%
90 Day-28.9%-1.5%-0.4%
1 Year-43.2%-43.2%-6.9%-7.7%9.3%6.9%
3 Yearn/a14.7%10.7%45.8%36.4%
5 Yearn/a-2.3%-7.0%62.9%45.1%

Price Volatility Vs. Market

How volatile is Celcuity's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Celcuity undervalued compared to its fair value and its price relative to the market?

7.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate CELC's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate CELC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CELC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CELC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CELC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CELC is overvalued based on its PB Ratio (7.3x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Celcuity forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-0.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CELC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CELC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CELC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CELC's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CELC's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if CELC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Celcuity performed over the past 5 years?

-30.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CELC is unprofitable, and losses have increased over the past 5 years at a rate of -30.2% per year.

Accelerating Growth: Unable to compare CELC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CELC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: CELC has a negative Return on Equity (-32.43%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CELC is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CELC is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Celcuity's financial position?


Financial Position Analysis

Short Term Liabilities: CELC's short term assets ($22.4M) exceeds its short term liabilities ($885.5K)

Long Term Liabilities: CELC's short term assets (22.4M) exceeds its long term liabilities (163.5K)


Debt to Equity History and Analysis

Debt Level: CELC is debt free.

Reducing Debt: CELC had no debt 5 years ago.


Balance Sheet

Inventory Level: CELC has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CELC's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CELC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CELC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -30.5% each year


Next Steps

Dividend

What is Celcuity's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CELC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CELC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CELC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CELC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CELC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Celcuity's salary, the management and board of directors tenure and is there insider trading?

5.0yrs

Average management tenure


CEO

Brian Sullivan (57yo)

7.8yrs

Tenure

US$564,196

Compensation

Mr. Brian F. Sullivan is a Co-Founder of Celcuity Inc. and has been its Chairman and Chief Executive Officer since 2012 and served as its Chief Financial Officer. Mr. Sullivan co-founded Entegris, Inc. in  ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Brian's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

5.0yrs

Average Tenure

57yo

Average Age

Experienced Management: CELC's management team is seasoned and experienced (5 years average tenure).


Board Age and Tenure

5.3yrs

Average Tenure

64yo

Average Age

Experienced Board: CELC's board of directors are considered experienced (5.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Brian Sullivan (57yo)

    Co-Founder

    • Tenure: 7.8yrs
    • Compensation: US$564.20k
  • Vicky Hahne (53yo)

    Chief Financial Officer

    • Tenure: 2.3yrs
    • Compensation: US$242.16k
  • Eric Lindquist

    Chief Business Officer

    • Tenure: 0.08yrs
  • Lance Laing (57yo)

    Co-Founder

    • Tenure: 7.8yrs
    • Compensation: US$411.11k

Board Members

  • Dick Nigon (71yo)

    Independent Director

    • Tenure: 2.8yrs
    • Compensation: US$50.00k
  • Brian Sullivan (57yo)

    Co-Founder

    • Tenure: 7.8yrs
    • Compensation: US$564.20k
  • Leo Furcht (72yo)

    Director

    • Tenure: 0.4yrs
  • Ronald McGlennen

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Lance Laing (57yo)

    Co-Founder

    • Tenure: 7.8yrs
    • Compensation: US$411.11k
  • Edward Greeno

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Sara Hurvitz

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Carol Lange

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Benita Katzenellenbogen

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • John Katzenellengogen

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Celcuity Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Celcuity Inc.
  • Ticker: CELC
  • Exchange: NasdaqCM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$164.441m
  • Shares outstanding: 10.24m
  • Website: https://www.celcuity.com

Number of Employees


Location

  • Celcuity Inc.
  • 16305–36th Avenue North
  • Suite 100
  • Minneapolis
  • Minnesota
  • 55446
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CELCNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDSep 2017

Biography

Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 00:28
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.